Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

PD-1/VEGF Combos a Next Step for RCC Treatment

January 20th 2017

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

Rini Stresses Axitinib Remains Significant in RCC

January 20th 2017

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Dr. Agarwal on Toxicities With Checkpoint Inhibitors in RCC

January 20th 2017

Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Dr. Petrylak on Sequencing of Targeted Agents in Bladder Cancer

January 20th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.

Dr. Motzer on Nivolumab Versus Everolimus in Renal Call Carcinoma

January 18th 2017

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Researcher Discusses Optimal Sequencing in Advanced RCC

January 16th 2017

Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.

Dr. McDermott on VEGF Plus PD-1 in Renal Cell Carcinoma

January 14th 2017

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

Dr. Hamieh on Characterization of Poor-Risk Metastatic Kidney Cancer

January 14th 2017

Lana Hamieh, MD, research fellow in Medicine at Brigham and Women’s Hospital, discusses characterization of patients with poor-risk metastatic renal cell carcinoma.

Dr. Sklar on the Role of Nivolumab in Bladder Cancer

January 10th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.

FDA Grants Atezolizumab Priority Review for Second Bladder Cancer Indication

January 10th 2017

The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

Dr. Hammers on Nivolumab/Ipilimumab Data in RCC

January 7th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Odisho on a Risk Prediction Model in Renal Cell Carcinoma

January 6th 2017

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

The Times They Are a Changin'

January 5th 2017

As a result of the most recent presidential election, it is a big unknown what the new administration will bring as it relates to the future of healthcare in the US.

Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer

January 4th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Two Landmark Conferences Contribute to Progress in Kidney and Bladder Cancers

January 4th 2017

The tail-end of this year saw 2 annual conferences occurring at the same time: the 2016 Large Urology Group Practice Association annual meeting in Chicago, and the 15th annual International Kidney Cancer Symposium in Miami. Both are covered in this issue’s Conference Highlights section, featuring key stories and landmark research in their respective fields.

Amid Explosion of Novel Agents, Chemo Could Still Have Curative Role in Urothelial Carcinoma

December 15th 2016

Even with 1 FDA approval of an immunotherapeutic agent in urothelial carcinoma—and more expected in the coming months—chemotherapy regimens will continue to play a pivotal part in the treatment of patients with this disease.

After Second-Line RCC Approvals, Focus Shifts to Frontline

December 15th 2016

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma, and researchers are now setting their sights on transforming upfront care.

Additional Research Required for Immunotherapy to Replace Chemo in Upfront Bladder Cancer Care

December 13th 2016

Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.

FDA Grants Priority Review to Durvalumab in Bladder Cancer

December 10th 2016

The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Immunotherapy Makes Comeback in RCC, But Challenges Remain

December 6th 2016

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.